AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting

-- AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectru...

Related Keywords

United States ,Germany ,Cambridge ,Cambridgeshire ,United Kingdom ,Ludwigshafen ,Rheinland Pfalz ,Massachusetts ,American ,Lou Gehrig ,Coadministered Atogepant ,Foslevodopa Foscarbidopa ,Instagram ,Linkedin ,Foundational Neuroscience Center ,Twitter ,Drug Administration ,Youtube ,Neuroscience Development ,Facebook ,American Academy Of Neurology ,Annual Meeting ,Michael Gold ,Therapeutic Area Head ,Cortical Spreading Depression ,Monthly Headache Days ,Migraine Related Quality ,Migraine Days ,Acute Medication Use Days ,Migraine Specific Quality ,Post Hoc Analysis ,Migraine Attacks ,Healthcare Resource Utilization ,Diagnosed Drug Induced Headache ,Potential Acute Medication Overuse ,Person Analysis ,Ubrogepant Treatment ,Mild Versus Moderate Severe Headache Pain ,Term Safety Extension Trial ,Pharmacokinetic Interaction ,Long Term Safety ,Oral Atogepant ,Once Daily ,Preventive Treatment ,Multicenter Extension ,Cardiovascular Disease Risk Factors ,Once Daily Shows Efficacy ,Week Open Label Extension Trial ,Body Weight ,Once Daily Atogepant ,World Persistence ,Costs Among Patients ,Chronic Migraine Treated ,Retrospective Claims Analysis Study ,Real World Use ,Acute Treatment ,Anti Calcitonin Gene ,Related Peptide Monoclonal Antibody Preventive ,Person Consistency ,Acute Treatment Success ,Long Term Safety Study ,World Effectiveness ,Migraine When Used ,Ubrogepant Among Participants ,Prior Treatment Failure ,Subgroup Analysis ,Novel Approach ,Defining Success ,Demonstrating Therapeutic Benefit ,Hour Post Dose ,Day Subcutaneous Infusion ,Advanced Parkinson ,Disease During ,Month Interim Results ,Long Term Effectiveness ,Levodopa Carbidopa Intestinal Gel ,Non Motor Symptom Benefits ,Disease Treated ,Baseline Hoehn ,Yahr Stage ,Final Analysis ,Multinational Observational Study ,Antibody Conversion ,Global Studies Across Multiple Indications ,Resource Utilization ,Stroke Related Spasticity Before ,After Treatment ,Virtual Reality Platform ,Facilitate Training ,Lower Limb Spasticity ,Disease Severity ,Presentation Subtype ,Onabotulinumtoxina Utilization ,Cervical Dystonia ,Medication Guide ,Product Information ,Prescribing Information ,Neuroscience Discovery ,Allergan Aesthetics ,